ICI Therapy May Reduce Asthma Exacerbations
Patients receiving Immune checkpoint inhibitors (ICI) pembrolizumab or nivolumab exhibited a modest reduction in asthma exacerbation rates at 24 months.
Tag: Keytruda Keytruda Qlex
All
Latest
ICI Therapy May Reduce Asthma Exacerbations
Patients receiving Immune checkpoint inhibitors (ICI) pembrolizumab or nivolumab exhibited a modest reduction in asthma exacerbation rates at 24 months.
Read More
FDA Approves Keytruda Qlex for Subcutaneous Injection
As a subcutaneous injection, Keytruda Qlex may provide added convenience compared to IV Keytruda because it can be administered by HCPs in multiple settings.
Read More
Merck’s Keytruda Meets Primary Endpoint in Phase 3 Trial for Lung Cancer
The US Food and Drug Administration has accepted Merck’s new supplemental Biologics License Application based on data from the trial.
Read More
FDA Expands Use of Keytruda with Chemo for Lung Cancer
The FDA has granted expanded use of Merck’s immunotherapy lung cancer drug Keytruda in combination with Eli Lilly’s chemotherapy drug Alimta, reports Reuters.
Read More
Keytruda Approved for Advanced Non-small Cell Lung Cancer
Keytruda (pembrolizumab, Merck & Co) was just FDA-approved to treat patients with advanced (metastatic) NSCLC with tumors that express a protein called PD-L1, according to an agency news release.
Read More
New Data Investigating Merck’s Keytruda for NSCLC and Mesothelioma
Merck announced new data evaluating Keytruda, an anti-PD-1 therapy, in advanced non-small cell lung cancer and malignant pleural mesothelioma.
Read More
FDA Grants Breakthrough Therapy Designation to Keytruda for NSCLC
The FDA granted Breakthrough Therapy Designation to pembrolizumab (Keytruda, Merck) for certain non-small cell lung cancer (NSCLC) patients.
Read More
Keytruda (pembrolizumab) the First FDA-Approved Anti-PD-1 Therapy
The US FDA has approved pembrolizumab (Keytruda, Merck) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Read More